CannEpilTM available for Australian supply under Authorised Prescriber Scheme
First commercial-scale production and material revenues to commence from
MXC Investigational Medicinal Product (IMP)
• MXC’s Medicinal Cannabis based IMP, CannEpilTM is now available for supply in
Australia under the Authorised Prescriber Scheme
• Authorisation has been granted by the TGA to specialist prescribers who are now
authorised to supply CannEpilTM to patients in Australia
• Authorisation follows recent Human Research Ethics Committee endorsement
from St Vincent’s Hospital Melbourne for the use of CannEpilTM in the treatment
of adult patients with drug-resistant epilepsy
• Represents a major milestone for MXC, validating and confirming its seed-topharma
strategy with the start of commercial supply of its first IMP offering
• The Company expects this to initially generate $1 million in annualised revenue
from the initial base of approximately 100 patients
• CannEpilTM is expected to be available for supply in Australia by December 2018
MXC Price at posting:
5.1¢ Sentiment: None Disclosure: Held
